Thymosin Alpha-1
Thymic Immunomodulatory Peptide (28 Amino Acids)
Thymosin alpha-1 (Tα1) is a 28-amino acid peptide naturally produced by the thymus gland that plays a central role in immune system maturation and regulation. It has been approved as an immune modulator in over 35 countries and has been the subject of extensive clinical research in infectious disease, oncology, and immunodeficiency. Researchers study Tα1 for its unique ability to both enhance and regulate immune function without causing immune overstimulation.
Aliases: Zadaxin, Thymalfasin
- Research score
- 9/10
Key fact
Immune-modulating peptide approved in 35+ countries (Zadaxin). Bidirectional: enhances underactive immunity, moderates overactive immunity. Decades of clinical data.
Mechanism
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally produced by the thymus gland. It has pleiotropic immunomodulatory effects: stimulates T-cell maturation, proliferation, and differentiation; promotes dendritic cell maturation and antigen presentation via TLR2 and TLR9 signaling; enhances NK cell cytotoxicity; increases antibody responses; modulates cytokine production (IL-2, IFN-alpha, IFN-gamma upregulation); and can both upregulate suppressed immunity and downregulate overactive inflammatory responses. This bidirectional modulation makes it useful in both immunodeficiency and autoimmune contexts.
Evidence note
Established — Approved in 35+ countries (as Zadaxin/thymalfasin). Extensive human clinical data for hepatitis B/C, cancer adjuvant therapy, and immunodeficiency. Well-characterized safety profile over decades.
Studies
Thymosin alpha 1: a comprehensive literature review
Recognized for modifying, enhancing, and restoring immune function; decades of clinical use across multiple indications
Open sourceImmune Modulation with Thymosin Alpha 1 Treatment
Pleiotropic mechanism affecting multiple immune cell subsets; effective in immunosuppressed patients
Open source · PMID 27450734Thymalfasin (Zadaxin) — Regulatory Approval in 35+ Countries for Hepatitis B
Approved as immune modulator in over 35 countries for chronic hepatitis B treatment; extensive clinical safety data spanning decades
FAQ
Is thymosin alpha-1 an approved drug?
Yes — as Zadaxin (thymalfasin), it is approved in over 35 countries for chronic hepatitis B treatment. It is not FDA-approved in the US but has extensive international clinical use spanning decades, with one of the most robust safety profiles of any peptide.
Does thymosin alpha-1 boost or modulate the immune system?
It modulates — which is an important distinction. Tα1 upregulates immune responses that are underactive (immunodeficiency, chronic infections) and downregulates responses that are overactive (autoimmunity, excessive inflammation). This bidirectional "thermostat" effect via TLR2/TLR9 signaling is what distinguishes it from crude immune stimulants.
Is thymosin alpha-1 being used for long COVID?
Yes — it gained significant traction during the COVID era. Users in long COVID communities report improved energy and immune markers. Research suggests Tα1 may help engage persistent viral reservoirs by enhancing T-cell and dendritic cell function. Results are mixed but promising.
For research and educational use only. This content is not medical advice.